Vantage Health and Scripps Translational Science Institute form Strategic Partnership for Mobile Health Technology
Vantage Health Inc, (OTCQB: VNTH) and its parent company Nanobeak Inc. today announced that they have formed a strategic partnership with Scripps Translational Science Institute (STSI) for the advancement of mobile health technology.
Vantage Health is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a small device attached to a smartphone.
STSI’s Center for Digital Medicine is committed to helping in the development and research of novel mobile health devices to accelerate their uptake into clinical practice.
Through this strategic partnership, STSI will assist in the testing, evaluation and detection of certain basic Volatile Organic Compounds (VOCs) using Gas Chromatography and Mass Spectrometry to calibrate the results of the Vantage sensor through validation.
STSI will also assist in the testing, evaluation and detection of certain VOC’s commonly associated with Lung Cancer, using Gas Chromatography and Mass Spectrometry to calibrate the results of the Vantage sensor through validation. STSI and Vantage Health will collaborate in the planning and execution of clinical trials. The actual clinical trials are expected to be carried out at STSI, as well as a 2nd location in the Midwest and a 3rd location in New England.
STSI is a National Institutes of Health-sponsored consortium led by Scripps Health in collaboration with The Scripps Research Institute. Through this innovative partnership, STSI is leading the effort to translate the latest wireless and genetic medical technologies into high-quality, cost-effective treatments for patients. Scripps Health is an integrated not-for-profit health system based in San Diego with five hospital campuses and 26 outpatient clinics.
Commenting on today’s announcement, Jeremy Barbera, chairman and CEO of Vantage Health stated, “This is arguably one of the most vital and exciting steps in our effort to transfer the technology out of the labs at NASA and into the marketplace, as part of our commercialization process. STSI’s Center for Digital Medicine, under the leadership of STSI Director Eric Topol, M.D., and Scripps Health digital medicine Director Steven Steinhubl, M.D., bring to Vantage the expertise and clinical trial experience necessary to successfully advance our mobile health applications.”
Dr. Steinhubl said, “This kind of collaboration is essential for the testing and validation of wireless and mobile health technologies. It offers the chance for transformational changes in the way we diagnose and treat a wide range of conditions.”
About Vantage Health Inc.
Vantage Health Inc. – a leader in mobile health technology – is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a small device attached to a smartphone.
With its foundations in advanced nanotechnology, the company’s first product, the Vantage Health Sensor, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The first mobile App is expected to be for lung cancer screening with additional mobile healthcare Apps in the planning stages. The company has offices in Redwood City, CA and New York. For more information, please visit http://www.vantagehealthinc.com
About Scripps Translational Science Institute Part of San Diego, Calif.-based Scripps Health, and the Scripps Translational Science Institute (STSI) is a unique community collaboration that initiates research that moves basic science from the lab to the patient bedside. STSI is supported by the NIH flagship program, Clinical and Translational Science Award (CTSA), awarded to The Scripps Research Institute in conjunction with its collaboration with STSI. The San Diego Supercomputer Center also is a collaborator in the STSI consortium. More information can be found at www.stsiweb.org.
Contact: Christine Petraglia
CSIR Group Investor Relations (212)386-7082 Investors@csirgroup.com
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. Such forward-looking statements may also include statements, among other things, concerning the efficacy, safety and intended utilization of Vantage’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include, among others, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Vantage may not obtain approval to market its product candidates, or outside financing may not be available to meet capital requirements. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s most recent Annual Report on Form 10-K and other periodic and other filings Vantage files with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Vantage assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.